Clinical Trials Logo

Clinical Trial Summary

The overall objective is to evaluate the long-term efficacy, safety and tolerability of repeated Lamazym i.v. treatment in patients 5-21 years of age with alpha-Mannosidosis


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01681940
Study type Interventional
Source Chiesi Farmaceutici S.p.A.
Contact
Status Completed
Phase Phase 2
Start date January 2012
Completion date September 2013

See also
  Status Clinical Trial Phase
Recruiting NCT02254863 - UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Phase 1
Not yet recruiting NCT06184503 - Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3
Completed NCT01908725 - Lamazym Aftercare Study Phase 3
Completed NCT02141503 - Clinical Biomarkers in Alpha-mannosidosis
Recruiting NCT02171104 - MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Phase 2
Withdrawn NCT04031066 - Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis Phase 3
Recruiting NCT03333200 - Longitudinal Study of Neurodegenerative Disorders
Completed NCT02478840 - Evaluation of Long-term Efficacy of Treatment With Lamazym Phase 3
Completed NCT02998879 - Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis Phase 2
Completed NCT01908712 - Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients Phase 3
Completed NCT01681953 - A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis Phase 3
Terminated NCT01372228 - Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Phase 1/Phase 2
Available NCT04959240 - Expanded Access to Velmanase Alfa